Eagle Global Advisors’s Biogen BIIB Stock Holding History

Eagle Global Advisors’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$564K	Buy	2,609 +9	+0.3%	+$1.72K	0.02%	205
2026 Q1	$477K	Hold	2,600	–	–	0.02%	212
2025 Q4	$458K	Sell	2,600 -25	-1%	-$4.08K	0.02%	215
2025 Q3	$368K	Hold	2,625	–	–	0.01%	234
2025 Q2	$330K	Hold	2,625	–	–	0.01%	226
2025 Q1	$359K	Hold	2,625	–	–	0.01%	222
2024 Q4	$401K	Hold	2,625	–	–	0.02%	209
2024 Q3	$509K	Hold	2,625	–	–	0.03%	180
2024 Q2	$609K	Hold	2,625	–	–	0.03%	164
2024 Q1	$566K	Hold	2,625	–	–	0.03%	165
2023 Q4	$679K	Hold	2,625	–	–	0.04%	158
2023 Q3	$675K	Hold	2,625	–	–	0.04%	157
2023 Q2	$748K	Hold	2,625	–	–	0.05%	154
2023 Q1	$730K	Hold	2,625	–	–	0.05%	151
2022 Q4	$727K	Hold	2,625	–	–	0.05%	149
2022 Q3	$701K	Hold	2,625	–	–	0.05%	152
2022 Q2	$535K	Hold	2,625	–	–	0.04%	155
2022 Q1	$553K	Hold	2,625	–	–	0.03%	165
2021 Q4	$630K	Hold	2,625	–	–	0.04%	161
2021 Q3	$743K	Hold	2,625	–	–	0.05%	156
2021 Q2	$909K	Hold	2,625	–	–	0.06%	152
2021 Q1	$734K	Hold	2,625	–	–	0.05%	159
2020 Q4	$643K	Hold	2,625	–	–	0.05%	150
2020 Q3	$745K	Hold	2,625	–	–	0.07%	132
2020 Q2	$702K	Hold	2,625	–	–	0.06%	137
2020 Q1	$830K	Hold	2,625	–	–	0.08%	128
2019 Q4	$779K	Hold	2,625	–	–	0.04%	148
2019 Q3	$611K	Hold	2,625	–	–	0.03%	152
2019 Q2	$614K	Hold	2,625	–	–	0.02%	162
2019 Q1	$620K	Buy	2,625 +25	+1%	+$7.87K	0.02%	161
2018 Q4	$782K	Hold	2,600	–	–	0.03%	147
2018 Q3	$919K	Hold	2,600	–	–	0.03%	148
2018 Q2	$755K	Hold	2,600	–	–	0.02%	156
2018 Q1	$712K	Hold	2,600	–	–	0.02%	162
2017 Q4	$828K	Hold	2,600	–	–	0.03%	156
2017 Q3	$814K	Sell	2,600 -791	-23%	-$234K	0.02%	156
2017 Q2	$920K	Buy	3,391 +363	+12%	+$96K	0.03%	153
2017 Q1	$828K	Buy	3,028 +428	+16%	+$121K	0.02%	162
2016 Q4	$737K	Hold	2,600	–	–	0.02%	170
2016 Q3	$814K	Hold	2,600	–	–	0.02%	156
2016 Q2	$629K	Hold	2,600	–	–	0.02%	173
2016 Q1	$677K	Hold	2,600	–	–	0.02%	164
2015 Q4	$797K	Hold	2,600	–	–	0.03%	156
2015 Q3	$759K	Hold	2,600	–	–	0.03%	159
2015 Q2	$1.05M	Hold	2,600	–	–	0.03%	162
2015 Q1	$1.1M	Hold	2,600	–	–	0.03%	155
2014 Q4	$883K	Hold	2,600	–	–	0.02%	172
2014 Q3	$860K	Hold	2,600	–	–	0.02%	173
2014 Q2	$820K	Hold	2,600	–	–	0.02%	163
2014 Q1	$795K	Hold	2,600	–	–	0.02%	162
2013 Q4	$727K	Hold	2,600	–	–	0.02%	165
2013 Q3	$626K	Hold	2,600	–	–	0.02%	168
2013 Q2	$560K	Buy	+2,600	New	+$556K	0.02%	161

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Eagle Global Advisors's BIIB Position: Q2 2026 in Review

Eagle Global Advisors increased its Biogen (BIIB) stake by 0.35% in Q2 2026, buying an estimated $1.72K and bringing the position to 2,609 shares worth $564K. The position accounts for 0.02% of the portfolio, ranked #205.

Eagle Global Advisors first reported a position in BIIB in Q2 2013 and has held it in 53 quarters since. The position peaked at $1.1M in Q1 2015. 569 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Eagle Global Advisors held 2,609 shares of Biogen worth $564K as of Q2 2026.
Eagle Global Advisors bought 9 Biogen shares in Q2 2026, an estimated $1.72K.
Biogen made up 0.02% of Eagle Global Advisors's portfolio in Q2 2026, its #205 holding.
Eagle Global Advisors first reported a position in Biogen in Q2 2013 and has held it in 53 quarters since.
Eagle Global Advisors's Biogen position peaked at $1.1M in Q1 2015.
569 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Eagle Global Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.